Literature DB >> 10838609

The endocannabinoid system as a target for therapeutic drugs.

D Piomelli1, A Giuffrida, A Calignano, F Rodríguez de Fonseca.   

Abstract

Cannabinoid receptors, the molecular targets of the cannabis constituent Delta9-tetrahydrocannabinol, are present throughout the body and are normally bound by a family of endogenous lipids - the endocannabinoids. Release of endocannabinoids is stimulated in a receptor-dependent manner by neurotransmitters and requires the enzymatic cleavage of phospholipid precursors present in the membranes of neurons and other cells. Once released, the endocannabinoids activate cannabinoid receptors on nearby cells and are rapidly inactivated by transport and subsequent enzymatic hydrolysis. These compounds might act near their site of synthesis to serve a variety of regulatory functions, some of which are now beginning to be understood. Recent advances in the biochemistry and pharmacology of the endocannabinoid system in relation to the opportunities that this system offers for the development of novel therapeutic agents will be discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10838609     DOI: 10.1016/s0165-6147(00)01482-6

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  95 in total

1.  Cannabinoids for pain and nausea.

Authors:  E Kalso
Journal:  BMJ       Date:  2001-07-07

2.  The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.

Authors:  Eleni T Tzavara; Richard J Davis; Kenneth W Perry; Xia Li; Craig Salhoff; Frank P Bymaster; Jeffrey M Witkin; George G Nomikos
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

Review 3.  Neurons on cannabinoids: dead or alive?

Authors:  Manuel Guzman
Journal:  Br J Pharmacol       Date:  2003-10       Impact factor: 8.739

4.  Moving bliss: a new anandamide transporter.

Authors:  Giovanni Marsicano; Francis Chaouloff
Journal:  Nat Neurosci       Date:  2011-12-23       Impact factor: 24.884

Review 5.  Role of G protein-coupled receptors in inflammation.

Authors:  Lei Sun; Richard D Ye
Journal:  Acta Pharmacol Sin       Date:  2012-02-27       Impact factor: 6.150

6.  Endocannabinoid Effects on Febrile Seizures: Not Just a Toke(n) Mechanism.

Authors:  Carl E Stafstrom
Journal:  Epilepsy Curr       Date:  2004-03       Impact factor: 7.500

7.  Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes.

Authors:  Régis Roche; Laurence Hoareau; Sandrine Bes-Houtmann; Marie-Paule Gonthier; Christine Laborde; Jean-François Baron; Yacine Haffaf; Maya Cesari; Franck Festy
Journal:  Histochem Cell Biol       Date:  2006-01-04       Impact factor: 4.304

8.  BDNF interacts with endocannabinoids to regulate cocaine-induced synaptic plasticity in mouse midbrain dopamine neurons.

Authors:  Peng Zhong; Yong Liu; Ying Hu; Tong Wang; Yong-ping Zhao; Qing-song Liu
Journal:  J Neurosci       Date:  2015-03-11       Impact factor: 6.167

9.  CB1 cannabinoid receptors increase neuronal precursor proliferation through AKT/glycogen synthase kinase-3beta/beta-catenin signaling.

Authors:  Stefania Trazzi; Martin Steger; Valentina Maria Mitrugno; Renata Bartesaghi; Elisabetta Ciani
Journal:  J Biol Chem       Date:  2010-01-18       Impact factor: 5.157

10.  Discovery of Potent Dual PPARα Agonists/CB1 Ligands.

Authors:  Ruth Pérez-Fernández; Nieves Fresno; Manuel Macías-González; José Elguero; Juan Decara; Rocío Girón; Ana Rodríguez-Álvarez; María Isabel Martín; Fernando Rodríguez de Fonseca; Pilar Goya
Journal:  ACS Med Chem Lett       Date:  2011-09-16       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.